Treatment of refractory anemia with ring sideroblasts associated with marked thrombocytosis with lenalidomide in a patient testing negative for 5q deletion and JAK2 V617F and MPL W515K/L mutations

Treatment of refractory anemia with ring sideroblasts associated with marked thrombocytosis with lenalidomide in a patient testing negative for 5q deletion and JAK2 V617F and MPL W515K/L mutations

Refractory anemia with ring sideroblasts associated with marked thrombocytosis (RARS-T) is a hematologic malignancy that often results in transfusion dependency and a hypercoagulable state. This rare disease currently lacks formal guidelines for treatment; however, various case reports have demonstr...

Full description

Bibliographic Details
Main Authors: Ryan Keen, Jeremy Pantin, Natasha Savage, Paul M. Dainer
Format: Article
Language:English
Published: MDPI AG 2016-11-01
Series:Hematology Reports
Subjects:
Myelodysplastic-myeloproliferative diseases
Anemia
Refractory
Platelet count
Lenalidomide
Online Access:http://www.pagepress.org/journals/index.php/hr/article/view/6592

Internet

http://www.pagepress.org/journals/index.php/hr/article/view/6592

Similar Items